266 related articles for article (PubMed ID: 17362522)
1. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.
Koh ES; Tran TH; Heydarian M; Sachs RK; Tsang RW; Brenner DJ; Pintilie M; Xu T; Chung J; Paul N; Hodgson DC
Radiat Oncol; 2007 Mar; 2():13. PubMed ID: 17362522
[TBL] [Abstract][Full Text] [Related]
2. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma.
Hodgson DC; Koh ES; Tran TH; Heydarian M; Tsang R; Pintilie M; Xu T; Huang L; Sachs RK; Brenner DJ
Cancer; 2007 Dec; 110(11):2576-86. PubMed ID: 17941006
[TBL] [Abstract][Full Text] [Related]
3. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
[TBL] [Abstract][Full Text] [Related]
4. 3-D reconstruction of anterior mantle-field techniques in Hodgkin's disease survivors: doses to cardiac structures.
Vordermark D; Seufert I; Schwab F; Kölbl O; Kung M; Angermann C; Flentje M
Radiat Oncol; 2006 Apr; 1():10. PubMed ID: 16722610
[TBL] [Abstract][Full Text] [Related]
5. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
Chera BS; Rodriguez C; Morris CG; Louis D; Yeung D; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1173-80. PubMed ID: 19386423
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
8. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
10. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
Maraldo MV; Jørgensen M; Brodin NP; Aznar MC; Vogelius IR; Petersen PM; Berthelsen AK; Christensen CB; Hjalgrim LL; Specht L
Pediatr Blood Cancer; 2014 Apr; 61(4):717-22. PubMed ID: 24660228
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.
De Bruin ML; Sparidans J; van't Veer MB; Noordijk EM; Louwman MW; Zijlstra JM; van den Berg H; Russell NS; Broeks A; Baaijens MH; Aleman BM; van Leeuwen FE
J Clin Oncol; 2009 Sep; 27(26):4239-46. PubMed ID: 19667275
[TBL] [Abstract][Full Text] [Related]
12. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma.
Jørgensen AY; Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Rosenschöld PM; Petersen PM; Specht L
Acta Oncol; 2013 Oct; 52(7):1559-65. PubMed ID: 24047340
[TBL] [Abstract][Full Text] [Related]
13. Late effects in the era of modern therapy for Hodgkin lymphoma.
Hodgson DC
Hematology Am Soc Hematol Educ Program; 2011; 2011():323-9. PubMed ID: 22160053
[TBL] [Abstract][Full Text] [Related]
14. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
Mazonakis M; Lyraraki E; Damilakis J
Med Phys; 2017 Jul; 44(7):3866-3874. PubMed ID: 28493609
[TBL] [Abstract][Full Text] [Related]
15. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
[TBL] [Abstract][Full Text] [Related]
17. [Radiotherapy in adults with localized supradiaphragmatic stages CS I/II of Hodgkin's disease. 2. The special aspects of radiotherapy: dosage, fractionation, focal volumes, risks, conclusions].
Glanzmann C; Lütolf UM
Strahlenther Onkol; 1993 Oct; 169(10):570-83. PubMed ID: 8235981
[TBL] [Abstract][Full Text] [Related]
18. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
[TBL] [Abstract][Full Text] [Related]
19. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
Kahn S; Flowers C; Xu Z; Esiashvili N
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):175-80. PubMed ID: 20732769
[TBL] [Abstract][Full Text] [Related]
20. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
Maraldo MV; Brodin P; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):297-303. PubMed ID: 23910709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
